While early bellwether trials in the GLP-1 MDL may shape outcomes for GI-related claims, this lawsuit remains distinct and may open the door for similar NAION cases in the future
At 1.25 mg, 50 units is a moderate amount
Plaintiffs allege that Ozempic and similar GLP-1 receptor agonist drugs have caused serious gastrointestinal complications, including gastroparesis (stomach paralysis), intestinal blockages, and chronic vomiting
We affiliate with dispensaries in the following jurisdictions that ship product to our customers: Canada, Mauritius, India, New Zealand, Australia, Turkey, and United Kingdom
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), have become widely prescribed for type 2 diabetes management and weight loss